Advances in Prognosis and Theranostics of Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 20240
Special Issue Editors
Interests: cancer theranostics; immunomodulatory biomaterials; angiogenesis; drug delivery; nanomedicine
Special Issues, Collections and Topics in MDPI journals
Interests: stem cells; iPSC; ESC; premalignancy; disease modeling; drug discovery; nanotechnology; lung cancer; immuno-oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Lung cancer is one of the leading causes of cancer-related death worldwide. As per the recent cancer statistics data, lung cancer accounts for an estimated 2.1 million lung cancer cases and 1.8 million deaths in 2018. Lung cancer recurs following surgery in approximately 30% of patients and therefore has long been the number-one cause of death from cancer. Moreover, the prevalence of lung cancer is not only rising in men but also strikingly rising amongst women, thus making it an urgent priority to tackle this devastating disease. Non-small cell lung cancer (NSCLC) causes around 80% of all lung cancer-related deaths. Although advances have been made in the treatment of NSCLC, the 5-year survival rate has increased by only 5% in the past 30 years. Another form of lung cancer, small cell lung cancer (SCLC) is less common but is more aggressive than NSCLC. The lack of an early diagnosis and inefficiency in conventional therapies causes poor prognosis and overall survival of lung cancer patients.
Hence alternative prognostic, therapeutic, and diagnostic approaches are required to reduce overall mortality and improve patient quality of life. In this present issue, we will publish research, reviews, and short communications on the modern approaches to combat lung cancer. Contributions on biomarker discovery, diagnosis, therapeutic modalities including immunotherapy, cancer vaccines, biomaterials-based theranostics approaches, nanomedicine-based theranostics, small molecule-based targeting, immunomodulatory approaches and other emergent approaches in precision oncology are also encouraged.
Dr. Sudip Mukherjee
Dr. Manash Paul
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Lung Cancer
- Biomarker
- Immunotherapy
- Theranostics
- Prognosis
- Cell Therapy
- Nanomedicine
- Immunomodulation
- Small molecule-based drugs
- Biomaterials